CLYM Climb Bio Inc.
Price (delayed)
$1.21
Market cap
$81.65M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.53
Enterprise value
-$5.05M
Highlights
Climb Bio's equity has soared by 97% YoY but it has decreased by 3.2% from the previous quarter
Climb Bio's EPS has increased by 28% from the previous quarter but it has decreased by 18% YoY
CLYM's net income has dropped by 110% year-on-year and by 7% since the previous quarter
CLYM's debt has soared by 52% year-on-year
Key stats
What are the main financial stats of CLYM
Market
Valuations
Earnings
Shares outstanding
67.48M
Market cap
$81.65M
Enterprise value
-$5.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$82.02M
Net income
-$73.9M
EBIT
-$73.9M
EBITDA
-$73.68M
Free cash flow
-$15.56M
Per share
Balance sheet
Liquidity
EPS
-$1.53
EPS diluted
-$1.53
Free cash flow per share
-$0.32
Book value per share
$3.15
Revenue per share
$0
TBVPS
$4.51
Total assets
$217.19M
Total liabilities
$5.31M
Debt
$532,000
Equity
$211.88M
Working capital
$149.94M
Debt to equity
0
Current ratio
31.41
Quick ratio
30.61
Net debt/EBITDA
1.18
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-38.2%
Return on equity
-38.9%
Return on invested capital
-148.5%
Return on capital employed
-34.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLYM stock price
How has the Climb Bio stock price performed over time
Intraday
0.83%
1 week
-6.92%
1 month
-16.55%
1 year
-56.94%
YTD
-32.78%
QTD
-0.82%
Financial performance
How have Climb Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$82.02M
Net income
-$73.9M
Gross margin
N/A
Net margin
N/A
CLYM's net income has dropped by 110% year-on-year and by 7% since the previous quarter
The operating income has plunged by 104% YoY and by 8% from the previous quarter
Growth
What is Climb Bio's growth rate over time
Valuation
What is Climb Bio stock price valuation
P/E
N/A
P/B
0.38
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Climb Bio's EPS has increased by 28% from the previous quarter but it has decreased by 18% YoY
Climb Bio's equity has soared by 97% YoY but it has decreased by 3.2% from the previous quarter
The price to book (P/B) is 58% less than the last 4 quarters average of 0.9
Efficiency
How efficient is Climb Bio business performance
CLYM's ROIC has shrunk by 153% YoY but it has soared by 53% QoQ
The return on assets has declined by 26% year-on-year but it rose by 8% since the previous quarter
The company's return on equity fell by 24% YoY but it rose by 8% QoQ
Dividends
What is CLYM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLYM.
Financial health
How did Climb Bio financials performed over time
The total assets has surged by 97% year-on-year but it has declined by 2.3% since the previous quarter
Climb Bio's total liabilities has soared by 85% YoY and by 55% from the previous quarter
CLYM's debt is 100% smaller than its equity
Climb Bio's equity has soared by 97% YoY but it has decreased by 3.2% from the previous quarter
CLYM's debt has soared by 52% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.